ACE2 inhibition leads to pulmonary fibrosis (Homo sapiens)
From WikiPathways
Description
AOP based on https://aopwiki.org/aops/319
Quality Tags
Ontology Terms
Bibliography
- Clerbaux LA, Amigó N, Amorim MJ, Bal-Price A, Batista Leite S, Beronius A, Bezemer GFG, Bostroem AC, Carusi A, Coecke S, Concha R, Daskalopoulos EP, De Bernardi F, Edrosa E, Edwards SW, Filipovska J, Garcia-Reyero N, Gavins FNE, Halappanavar S, Hargreaves AJ, Hogberg HT, Huynh MT, Jacobson D, Josephs-Spaulding J, Kim YJ, Kong HJ, Krebs CE, Lam A, Landesmann B, Layton A, Lee YO, Macmillan DS, Mantovani A, Margiotta-Casaluci L, Martens M, Masereeuw R, Mayasich SA, Mei LM, Mortensen H, Munoz Pineiro A, Nymark P, Ohayon E, Ojasi J, Paini A, Parissis N, Parvatam S, Pistollato F, Sachana M, Sørli JB, Sullivan KM, Sund J, Tanabe S, Tsaioun K, Vinken M, Viviani L, Waspe J, Willett C, Wittwehr C; ''COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease - 3rd CIAO AOP Design Workshop.''; ALTEX, 2022 PubMed Europe PMC Scholia
- Wittwehr C, Amorim MJ, Clerbaux LA, Krebs C, Landesmann B, Macmillan DS, Nymark P, Ram R, Garcia-Reyero N, Sachana M, Sullivan K, Sund J, Willett C; ''Understanding COVID-19 through adverse outcome pathways - 2nd CIAO AOP Design Workshop.''; ALTEX, 2021 PubMed Europe PMC Scholia
- Nymark P, Sachana M, Leite SB, Sund J, Krebs CE, Sullivan K, Edwards S, Viviani L, Willett C, Landesmann B, Wittwehr C; ''Systematic Organization of COVID-19 Data Supported by the Adverse Outcome Pathway Framework.''; Front Public Health, 2021 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
View all... |
Name | Type | Database reference | Comment |
---|---|---|---|
ACE2 inhibition | Pathway | 554 (WikiPathways) | |
AGTR1 activation | Key Event | 1851 (AOP-Wiki KE) | |
Angiotensin II receptor type 1 pathway | Pathway | 5036 (WikiPathways) | |
Collagen biosynthesis and modifying enzymes | Pathway | WP2725 (WikiPathways) | |
Increase activation, Nuclear factor kappa B (NF-kB) | Key Event | 1172 (AOP-Wiki KE) | |
Increased proinflammatory mediators | Key Event | 1496 (AOP-Wiki KE) | |
Increased, Reactive oxygen species | Key Event | 1115 (AOP-Wiki KE) | |
KE1276: Lung Fibrosis | Key Event | 1276 (AOP-Wiki KE) | |
KE1740: ACE2 inhibition | Key Event | 1740 (AOP-Wiki KE) | |
KE1743: Increased plasma Angiotensin II | Key Event | 1743 (AOP-Wiki KE) | |
KE1752: Increased Angiotensin II | Key Event | 1752 (AOP-Wiki KE) | |
KE68: Collagen Accumulation | Key Event | 68 (AOP-Wiki KE) | |
Metabolism of Angiotensinogen to Angiotensins | Pathway | WP2729 (WikiPathways) | |
NF-KB pathway | Pathway | WP4562 (WikiPathways) | |
Oxidative stress | Pathway | WP408 (WikiPathways) | |
Renin Angiotensin Aldosterone System | Pathway | WP4756 (WikiPathways) |
Annotated Interactions
No annotated interactions